1
. This prior research demonstrated selective degradation of BET bromodomain transcriptional co-activators (BRD2, BRD3, and BRD4) using heterobifunctional degraders that bridge BET bromodomains to an E3 ubiquitin ligase (cereblon, CRBN). The catalytic-like biochemical activity of these small molecules allows rapid and target-specific turnover without degradation of the ligand. Use of E3-binding heterobifunctional degraders has now been validated for BRD4 (refs. [1] [2] [3] [4] ) and extended to FKBP12 (ref. 1 ), ERRα 5 , RIPK2 (ref. 5 ) and BRD9 (ref. 6 ). Chemical probes established by this approach will powerfully enable the study of target biology; however, each of these requires the up-front identification of a target-selective ligand. We therefore envisioned a single, generalizable approach to rapidly degrade allele-specific protein chimeras for biological investigation and early target validation.
Tag-based technologies to influence protein homeostasis have been pursued intently in the discipline of chemical biology. Exemplary technologies include induced displacement of cryptic degrons 7 , degradation of HaloTag fusion proteins via hydrophobic tagging 8 or HaloPROTACs 9 , small-molecule-assisted shutoff (SMASh) 10 , and the auxin-inducible degron (AID) 11 . Selective stabilization of a target protein known as the Shield system has also been described. This system involves expression of a protein chimera involving a destabilized mutant allele of FKBP12, which is stabilized upon administration of a directed ligand, Shield-1 (ref. 12 ). This system has been well used to study gain of function in complex biological systems 13, 14 . Inspired by this research, we endeavored to create a comparable loss-of-function solution to resolve target biology and dependencies in cells and in mice.
Results

dTAG molecules engage FKBP12
F36V and CRBN. To establish the more generalizable concept of all-chemical protein degradation, we previously reported the feasibility of degrading a cytosolic prolyl isomerase, FKBP12 (FKBP1A, also referred to herein as FKBP12 WT ), by heterobifunctional degraders (dFKBP-1 (1 )) that recruit CRBN 1 . We initially considered expressing target proteins as an FKBP12 WT chimera for biological investigation but were concerned about the confounding biological effects of endogenous FKBP12
WT disruption. Engineered variants of FKBP12 were previously described by Ariad Pharmaceuticals (for example, FKBP12 F36V ) that create a cavity (or 'hole') in FKBP12, allowing selective recognition by a 'bumped' synthetic FKBP12 F36V -directed ligand, AP1867 (ref. 15 ).
The dTAG system for immediate and targetspecific protein degradation
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We hypothesized that an FKBP12 F36V chimera might be selectively degraded by heterobifunctional FKBP12 F36V and CRBN chemical inducers of dimerization (Fig. 1a) .
To this end, we appended CRBN ligands to AP1867 or a novel regioisomer (ortho-AP1867) with varying linker length and composition to create a series of heterobifunctional degraders (dTAG-7 (2 ), dTAG-13 (3 ), dTAG-48 (4 ) , and dTAG-51 (5 ); Fig. 1b and Supplementary Fig. 1a ). To biochemically evaluate the selectivity of these molecules, we developed FKBP12 WT , FKBP12 F36V , and CRBN-DDB1 ligand-displacement assays using a nanomaterial-based proximity assay (AlphaScreen) 16 . These experiments test the ability of dTAG molecules to compete for binding to FKBP12
WT and FKBP12 F36V with a biotin-conjugated FKBP12
WT -directed ligand (bio-SLF (6 )) or to CRBN with a biotin-conjugated thalidomide (bio-Thal (7 )) ( Supplementary Fig. 1b-e Table 1 ). In contrast, meta-substituted molecules (dTAG-48 and dTAG-51), despite being remarkably potent in their ability to engage FKBP12 F36V and CRBN, had significant affinity for FKBP12
WT . To assess the adaptor function of the putative chemical degraders, we developed a CRBN-DDB1/FKBP12
F36V dimerization assay, again using a luminescence proximity format as we previously reported for CRBN-DDB1/BRD4 (ref. 1 ; Supplementary Fig. 2d ). dFKBP-1 and all dTAG molecules exhibited a dose-dependent increase in luminescence, supporting effective heterodimerization of CRBN-DDB1 and FKBP12 F36V ( Fig. 1f and Supplementary  Fig. 2e ). As expected, loss of luminescence with excess concentrations of dTAG molecules was observed, obeying the characteristic 'hook effect' behavior 17 upon saturation of CRBN and FKBP12
F36V
binding sites. Collectively, these biochemical data identify dTAG-7 and dTAG-13 as FKBP12
-selective heterodimerizers that effectively engage FKBP12 F36V and CRBN.
Cellular target degradation by dTAG-7 and dTAG-13. To assay dose-dependent effects of FKBP12 WT and FKBP12 F36V degradation in cells, we employed a modified version of a dual luciferase assay 18 .
FKBP12
WT and FKBP12 F36V were subcloned as in-frame fusions to nanoluciferase (Nluc) and expressed on a multicistronic mRNA with control firefly luciferase (Fluc; Supplementary Fig. 3a ). Measurement of Nluc:Fluc ratios enables determination of FKBP12 fusion protein degradation relative to the internal Fluc control, independent of effects on transcription. We first transduced 293FT CRBN wildtype (293FT -Nluc, corroborating our biochemical experiments demonstrating that dTAG-48 exhibits off-target activity (Fig. 2a, Supplementary Fig. 3b and Supplementary Table 2 ). We further evaluated the selectivity of our dTAG molecules by monitoring degradation of IKZF1, a previously described neosubstrate of CRBN upon immunomodulatory drug treatment 18, 19 , using a dual luciferase IKZF1 reporter system in 293T cells 18 . Compared to lenalidomide and pomalidomide, treatment with dTAG-7, dTAG-13 and dTAG-48 had a limited effect on bioluminescent signal, indicating little to no off-target IKZF1 activity ( Supplementary Fig. 3c,d and Supplementary Table 3 ). However, dTAG-51 diminished bioluminescent signal to levels comparable to those observed with lenalidomide and pomalidomide, indicating off-target activity toward IKZF1. Due to the limited off-target activity toward FKBP12
WT and IKZF1, we selected dTAG-7 and dTAG-13 as lead heterobifunctional degraders for further characterization.
To evaluate the potency, selectivity, and CRBN dependency of dTAG-7 and dTAG-13 in cells, we transduced isogenic 293FT CRBN-deficient (293FT (Fig. 2b,c) . dTAG-7 and dTAG-13 treatment did not alter the levels of endogenous FKBP12 WT or exogenous FKBP12
WT -Nluc (Fig. 2b) . Temporal analysis revealed that treatment with dTAG-13 led to rapid degradation of FKBP12 F36V -Nluc in 293FT
WT cells as early as 1 h after treatment (Fig. 2d) . Notably, these data compare very favorably to a peptide-based proteolysis targeting chimeric molecules (PROTAC) approach that targeted EGFP-FKBP12 F36V for degradation with HIF1α -peptides 20 , in which apparent activity was observed at 25 μ M ligand concentration.
To corroborate the cellular requirement of CRBN binding, E3 complex activation, and proteasome function for effective target degradation, we pretreated 293FT
WT cells stably expressing FKBP12
F36V
-Nluc separately with carfilzomib (proteasome inhibitor), MLN4924 (Nedd8 activating enzyme inhibitor), or lenalidomide (CRBN binder) before applying dTAG-13. Each co-incubation attenuated target degradation, consistent with a requirement for functional engagement of the ubiquitin-proteasome system, cullin-RING E3 ligases, and CRBN (Fig. 2e) . Collectively, these data indicate that dTAG-7 and dTAG-13 treatment leads to rapid and selective CRBN-mediated degradation of FKBP12 F36V in cells.
BRD4 degradation by CRISPR-mediated FKBP12
F36V knock-in. Having established allele-specific degradation by our dTAG molecules, we next endeavored to knock-in FKBP12 F36V at a genomic locus to provide control over a discrete, endogenously expressed target. BET bromodomains (BRD2, BRD3, and BRD4) are co-activator proteins that influence elongation of RNA polymerase in the context of gene expression [21] [22] [23] [24] [25] . The study of BET bromodomains has been powerfully facilitated by inhibitors and degraders that we and others have innovated 26 (for example, JQ1 (ref. 27 ), MT1 (ref. 28 ), dBET1 (ref. 1 ), and dBET6 (ref. 4 )), but these compounds do not discriminate between BET isoforms. We therefore sought to knock-in FKBP12 F36V at the BRD4 genomic locus to pharmacologically control a single BET bromodomain protein.
First, we tested the feasibility of degrading exogenously expressed FKBP12 F36V ) chimera with any target gene using a Gateway recombination cloning strategy (Fig. 3a) . Each plasmid includes two tandem HA-tags for immunodetection of gene products and a puromycin selectable marker. We first subcloned in the short isoform of BRD4 and stably expressed BRD4(short)-FKBP12 F36V in MV4;11 cells. Treatment of MV4;11 cells expressing BRD4(short)-FKBP12 F36V with dTAG-7 and dTAG-13 led to robust degradation of BRD4 ( Supplementary Fig. 4a ). Treatment with dTAG-13 led to rapid degradation of BRD4 within 1 h, with no effect on endogenous FKBP12
WT (Fig. 3a) . Having established the feasibility of degrading a BRD4-FKBP12 F36V chimera, we next developed a means to knock-in FKBP12 F36V into the N or C terminus of BRD4 using a modified version of the Precise Integration into Target Chromosome (PITCh) system 29 . This strategy employs microhomology-mediated end-joining
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(MMEJ) to achieve selective knock-in and does not require large homology arms. We cloned an N-or C-terminal-targeting BRD4 sgRNA into the pX330A PITCh vector, which expresses a PITChsgRNA and Cas9. We also modified the pCRIS-PITChv2 donor vector by replacing the original EGFP-2A-Puro cassette with a cassette that includes a blasticidin selectable marker (BSD), a P2A sequence, two tandem HA-tags, and FKBP12
F36V
, which is flanked by 5′ and 3′ BRD4 microhomology sequences (Fig. 3b) . To evaluate the efficiency of this approach, we co-transfected the N-or C-terminal-targeting constructs into 293T cells, which are notably hypotriploid. While we were unable to recover homozygous C-terminal FKBP12 F36V knock-in clones, we isolated clonal cell lines with heterozygous and homozygous N-terminal FKBP12 F36V knockin at the BRD4 locus, prompting further characterization of these cells ( Supplementary Fig. 4b-d) .
We first examined the consequences of dTAG treatment on BRD4 function and stability compared to treatment with a pan-BET bromodomain inhibitor (JQ1) or degrader (dBET6). Treatment 
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with dTAG-13 led to rapid and potent degradation of the BRD4 fusion chimera in the heterozygous and homozygous knock-in clones but had no effect on endogenous FKBP12 WT (Fig. 3c,d and Supplementary Fig. 5a ). Importantly, we did not detect changes in BRD2 or BRD3 protein levels in FKBP12 F36V knock-in clones and did not detect changes in BRD2, BRD3, or BRD4 levels in wildtype cells, establishing a powerful chemical-genetic system to study BRD4 function in isolation from BRD2 and BRD3. Upon treatment with dBET6, we confirmed the degradability of BRD2, BRD3, and BRD4 in wild-type cells and FKBP12 F36V knock-in clones (Fig. 3c,d and Supplementary Fig. 5a ). BRD4 degradation was also observed with dTAG-7 treatment, whereas BRD4 and FKBP12
WT degradation was observed with dTAG-48, further confirming the selectivity of dTAG-7 and the affinity of dTAG-48 toward both FKBP12
WT and FKBP12 F36V ( Supplementary Fig. 5a ). We recently demonstrated that pan-BET bromodomain degradation results in a collapse of global transcriptional elongation 4 . Leveraging the selective BRD4 degradation afforded by the dTAG system, we tested whether BRD4 alone was required for productive transcriptional elongation by monitoring RNA polymerase II (Pol II) phosphorylation on the C-terminal repeat domain (CTD) at serine 2 (pS2). Whereas the degradation of pan-BET bromodomain upon dBET6 treatment led to a rapid decrease in Pol II pS2, selective BRD4 degradation upon dTAG-13 treatment had no observable effect on Pol II pS2 levels in 293T cells (Fig. 3d ). This suggests that BRD4 alone is not required for Pol II CTD phosphorylation in 293T cells, although we anticipate that the contributions of individual BET bromodomains will be context dependent. We next explored the differential effects of BRD4 loss compared to those from pan-BET bromodomain inhibition or degradation on cellular proliferation. In the homozygous BRD4 knock-in clone, treatment with dTAG-7 and dTAG-13 led to a modest antiproliferative effect, whereas treatment with JQ1 or dBET6 had a significantly greater impact (lower E max ; Fig. 3e ). 293T
WT cells and the heterozygous BRD4 knock-in clone were similarly sensitive to JQ1 and dBET6 treatment and insensitive to dTAG-7 and dTAG-13 treatment, further confirming selectivity of the dTAG molecules. These data suggest that BRD2 and BRD3 may partially compensate for the loss of BRD4 in 293T cells and that pan-BET bromodomain activity of inhibitors or degraders is important for achieving maximal antiproliferative effects in this cellular context. Generalizability of dTAG to study divergent proteins. With the successful degradation of the BRD4 fusion chimera, we used our facile N-and C-terminal lentiviral expression system to assess pharmacological CRBN-mediated degradation of diverse target proteins. In parallel, we cloned a panel of wild-type and mutant genes, generating N-terminal fusions, including FKBP12 . Upon stable expression of these fusion chimeras in MV4;11 cells, we evaluated degradation upon treatment with dTAG-7 or dTAG-13. Each fusion chimera was potently degraded with as little as 50 nM of dTAG-7 or dTAG-13, supporting the generalizable nature of this approach ( Supplementary Fig. 5b ). We also compared the kinetics of degradation of each fusion chimera upon treatment with dTAG-13 ( kinetics of degradation. These data further validate rapid and potent degradation of nuclear and cytoplasmic tagged proteins using the dTAG system.
Immediate effects of KRAS
G12V loss on cellular signaling. To establish the utility of the dTAG system in the setting of fast biology, we selected FKBP12
F36V
-KRAS G12V for further study. RAS proteins interact with downstream signaling effectors to promote cellular growth, survival, migration, and differentiation 30 . In cancer, RAS family members (KRAS, NRAS, and HRAS) are, together, among the most prevalent oncogenes, with KRAS lesions predominating in aggressive epithelial malignancies 31 . Although KRAS has been largely impervious to coordinated efforts in drug discovery, Articles NATURE ChEMICAl BIoloGy chemical degradation comprises a potentially new path to RAStargeted therapeutics, as heterobifunctional degraders could disassociate the need for active site-directed ligands.
To model the mechanism and consequence of allosteric sitemediated mutant KRAS degradation, in advance of possessing heretofore elusive chemical matter, we stably expressed FKBP12 F36V -KRAS G12V in murine NIH/3T3 cells. Stable expression of the chimeric oncoprotein led to characteristic changes in signaling, morphology, and growth, akin to those observed in focused studies of mutant RAS [32] [33] [34] . FKBP12
F36V -KRAS
G12V expression increased phosphorylation of MEK (pMEK) and AKT (pAKT), indicating that the chimeric oncoprotein is functional (Fig. 4b,c) . Treatment with dTAG-13 led to rapid and pronounced degradation of FKBP12 F36V -KRAS G12V , whereas treatment with dTAG-7 resulted in modest degradation at high doses; we therefore focused on dTAG-13 for further characterization (Fig. 4b,c and Supplementary Fig. 6a ). Strikingly, FKBP12
F36V
-KRAS G12V degradation decreased pMEK and pAKT to baseline levels within 1 h of dTAG-13 treatment (Fig. 4c) . Washout of dTAG-13 led to rapid recovery of FKBP12 -KRAS G12V expressing cells in S-phase, which returned to control NIH/3T3 levels in 48 h and a significant antiproliferative effect in 72 h (Fig. 4f,g ). Collectively, these data demonstrate that FKBP12 We next used multiplexed quantitative mass spectrometry-based proteomics 35, 36 and phosphoproteomics 37 to evaluate the specificity and consequences of FKBP12 F36V -KRAS G12V degradation upon dTAG-13 treatment. In the proteomics analysis, 8,164 proteins qualified for quantification (Supplementary Dataset 1). Despite the high conservation between mouse Kras and human KRAS, as well as mouse Fkbp1a and human FKBP1a, we were able to monitor two peptides unique to FKBP12 F36V -KRAS G12V (KKVGTMTEYKL and KLEGGYPYDVPDYAGYPYDVPDYAGIDRS). Using these signature peptides, we observed highly significant and selective depletion of FKBP12 F36V -KRAS G12V upon treatment with dTAG-13 (58.3% at 1 h and 88.6% at 4 h; Fig. 5a ). Endogenous mouse Kras and mouse Fkbp1a peptides that were quantified are conserved between mouse and human, and therefore likely represent both human and murine peptides. Although we observe partial depletion of endogenous mouse Kras and Fkbp1a peptides, these differences are likely due to changes in the human fusion chimera upon degradation and not because of endogenous mouse protein levels. In the phosphoproteomics analysis, 8,316 phosphoserine/threonine and 33 phosphotyrosine sites qualified for quantification (Supplementary Datasets 2 and 3). Focusing on unique phosphoserine/threonine sites, we observed highly significant reductions in the doubly phosphorylated activation loop of Mapk3 (Erk1) and Mapk1 (Erk2) at 1 h and 4 h of dTAG-13 treatment, further confirming the functionality of the KRAS G12V fusion chimera ( Fig. 5b and Supplementary Fig. 7a ). No effect on total Mapk1 or Mapk3 levels was detected ( Supplementary  Fig. 7b ). We also observed highly significant reductions in previously described Jun 38 , Myc 39 , and Palld 40 phosphosites, as well as chromatin regulators including Chd8 and Trim33. Together, these data support the high degree of potency and selectivity of KRAS G12V degradation using the dTAG system and highlight the immediate collapse of cellular signaling upon KRAS G12V degradation.
KRAS G12V loss rapidly alters transcriptional signaling. Temporal quantitative proteomics and phosphoproteomics revealed that FKBP12
F36V -KRAS G12V degradation rapidly diminished pERK1 and pERK2 within 1 h and ERK pathway dependent proteins including Jun, Sema7a, and Angptl4 within 4 h, suggesting that KRAS G12V degradation triggered acute transcriptional changes (Fig. 5a,b) . Prior to evaluating the consequences of FKBP12 F36V -KRAS G12V degradation on the transcriptome, we treated parental NIH/3T3 cells with dTAG-13 and performed RNA-sequencing to evaluate off-target transcriptional changes. No significantly differentially expressed genes were identified upon dTAG-13 treatment, further validating the high degree of selectivity of dTAG-13 ( Supplementary Fig. 7c ). As expected, dBET6 treatment led to a collapse in the NIH/3T3 gene expression program. Having established the limited off-target activity of dTAG-13, we performed RNA-sequencing to quantify the acute transcriptional changes upon FKBP12 F36V -KRAS G12V degradation using dTAG-13 and MEK inhibition via trametinib (GSK112021), an allosteric MEK1/2 inhibitor approved for use in BRAF-mutant metastatic melanoma 41, 42 . A 10-nM dose of trametinib was used for these experiments, as the reduction in pERK levels and antiproliferative effect at this dose were similar to levels achieved upon FKBP12
F36V
-KRAS G12V degradation with dTAG-13 ( Supplementary Fig. 8a,b -KRAS G12V or treatment with dTAG-13, as well as between genes differentially expressed upon treatment with dTAG-13 or trametinib, suggesting that acute KRAS G12V degradation predominantly alters ERK pathway genes (Fig. 5d) . Furthermore, gene set enrichment analysis (GSEA) revealed significant on-pathway enrichment of 'KRAS Up' signatures in DMSO treated FKBP12 F36V -KRAS G12V cells, and 'KRAS Down' signatures in dTAG-13 or trametinib treated cells ( Supplementary Fig. 9b ). Ingenuity Pathway Analysis identified similar deregulated signatures such as cellular growth and proliferation and cellular death and survival in each treatment comparison ( Supplementary Fig. 9c ). In summary, we find that KRAS G12V degradation rapidly alters ERK-dependent transcriptional signaling. In advance of discovery of selective mutant KRAS degraders, we present a chemical biology platform to evaluate the dynamic consequences of mutant KRAS degradation.
Rapid and potent degradation in vivo.
Having established extensible strategies to study target-specific degradation in cells, we endeavored to establish a system to evaluate degradation in living organisms. We aimed to use non-invasive bioluminescent measurements to report on the potency, kinetics, and recovery upon treatment with dTAG molecules. We stably expressed luciferase as a FKBP12
F36V chimera (luc-FKBP12 F36V ) in a human leukemia cell line (MV4;11) to enable non-invasive monitoring of ligand-induced target protein degradation in a highly aggressive disseminated leukemia model. Treatment of MV4;11 cells expressing luc-FKBP12 
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with dTAG-13 in vitro led to effective loss of bioluminescent signal (Fig. 6a) . Based on this potent degradation, and the favorable pharmacokinetic (PK) parameters of dTAG-13, we proceeded to evaluate dTAG-13 in vivo (Supplementary Table 4 Fig. 10a ). A significant, rapid, and durable effect on bioluminescent signal was observed 4 h after dTAG-13 administration, indicating effective degradation of luc-FKBP12 F36V (Fig. 6b,c) . Twenty-eight hours following the final treatment, we observed recovery of cellular bioluminescence to comparable levels between vehicle and dTAG-13 treatment groups. Together, these data support the use of the dTAG system to rapidly and reversibly evaluate the function of target proteins in living organisms.
Discussion
Chemical-genetic model systems capable of precise temporal control of target proteins can provide unique insights into cellular signaling and transcription. Here, we describe a series of dTAG molecules of varying linker composition, linker length, selectivity, and potency that recruit the CRBN E3 ligase complex to targets fused with FKBP12
F36V
. We present two generalizable approaches to engineer targeted protein degradation: a CRISPR-Cas9 system to achieve locus-specific FKBP12 F36V knock-in and a lentiviral system to exogenously express FKBP12 F36V fused to a target of interest. We show that ortho-substituted degraders dTAG-7 and dTAG-13 require CRBN to induce degradation, and are highly selective for FKBP12 F36V , typically exhibiting activity at submicromolar concentrations in cells. We also develop a model system to non-invasively evaluate in vivo degradation and demonstrate that dTAG-13 can induce potent degradation in living organisms. dTAG-13, which effectively induced rapid and potent target-specific degradation in all cell lines tested and in mice, will serve as a lead degrader for future studies.
Prior studies have achieved genetic knock-in of a destabilizing FKBP12 domain 14 and an AID tag 44 , allowing Shield-1 mediated stabilization or auxin-inducible degradation of endogenously tagged protein targets, respectively. In the AID approach, high doses of auxin and exogenous expression or knock-in of the SCF TIR1 E3 ubiquitin ligase substrate recognition component, TIR1, are required to achieve degradation. By contrast, our dTAG system relies on hijacking the cell's intrinsic degradation machinery, obviating the need to express additional ubiquitin proteasome system componentry. We recently achieved FKBP12 F36V knock-in at the YY1 locus using homology-directed repair, demonstrating that targeted degradation of YY1 disrupts enhancer-promoter loop formation and gene expression in murine embryonic stem cells 45 . Here, we employed a second knock-in strategy, the PITCh approach 29 , which uses MMEJ and eliminates the need for long homology arms. The cassettes used for these two strategies can be modified using Gibson assembly for FKBP12 F36V knock-in at any genomic locus. To demonstrate the feasibility of the modified PITCh approach, we generated clonal cell lines with homozygous N-terminal FKBP12 F36V knockin at the BRD4 locus. Though we were not successful in isolating clones with homozygous C-terminal FKBP12 F36V knock-in, it is possible that endogenous tagging altered the C-terminal positive transcription elongation factor (P-TEFb) interaction domain of BRD4, which is required for displacement of HEXIM1 and activation of experiments. b, Images of average radiance of vehicle (n = 6 biologically independent mice) or dTAG-13 (n = 5 biologically independent mice) treated mice. Three representative mice are shown, and the same mouse is shown on the same scale at each time point. c, Fold change in average radiance of each mouse normalized to baseline signal at day 0 of vehicle (n = 6 biologically independent mice) or dTAG-13 (n = 5 biologically independent mice) treated mice. P value derived from a two-tailed Welch's t-test. **P < 0.01 (P = 0.0025 for day 2 and P = 0.0048 for day 3).
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P-TEFb 46, 47 . When employing the dTAG system, we advise using our lentiviral plasmids to first evaluate exogenous expression of N-or C-terminally tagged targets to ensure protein functionality before CRISPR-mediated knock-in. Our N-terminal FKBP12 F36V knock-in BRD4 clones allowed comparisons between selective BRD4 degradation and pan-BET bromodomain inhibition or degradation. Selective BRD4 degradation had no effect on Pol II pS2 and led to a moderate antiproliferative effect, whereas inhibition and degradation of BRD2, BRD3 and BRD4 was significantly more efficacious in 293T cells. In this cellular context, these data support the mechanism-based clinical development of pan-BET bromodomain inhibitors or degraders and indicate that isoform-selective BET bromodomain inhibitors and degraders may display unique pharmacology compared to pan-BET bromodomain agents. Further efforts leveraging the dTAG system to evaluate contributions of BRD2, BRD3, and BRD4 in disease-relevant and BRD4-dependent contexts will aid in the assessment of selective BRD4 degradation.
In addition to genetic knock-in, prior studies have induced target-specific degradation by fusing target genes to FKBP12 F36V (ref. 20 
), FKBP12
F36V appended with a 19-residue cryptic degron 7 , a HaloTag 8, 9 , a SMASh tag 10 , or an AID tag 11 . Here, we developed a lentiviral expression system, amenable to Gateway cloning, as a facile means to express a target gene fused to FKBP12
F36V
. In contrast to the mechanisms of degradation implemented in the described approaches, we co-opted the CRBN E3 ligase machinery to rapidly degrade a panel of fusion chimeras (BRD4, HDAC1, EZH2, MYC, PLK1, and KRAS G12V ). We selected KRAS G12V to evaluate the functionality and efficacy of our chemical strategy due to the lack of available chemical matter to directly inhibit mutant KRAS. Though exciting progress has been made with covalent KRAS G12C inhibitors, inhibitors targeting other common KRAS mutants are far from clinical translation 30, 31 . Prior studies examined degradation of HaloTag fusions including HRAS G12V (ref. ), and ERK1 (ref. 9 ), but with limited assessment of the selectivity of these approaches, the functionality of HaloTag fusions, or the downstream consequences of HRAS G12V , MEK1, or ERK1 degradation. We leveraged the dTAG system to perform unbiased global temporal measurements to confirm the specificity of our dTAG molecules, to demonstrate the functionality of the KRAS G12V fusion chimera, and to identify the rapid proteomic and transcriptional signaling changes that occur upon acute KRAS G12V degradation. Our data provides further validation that pharmacological degradation can relieve the oncogenic effects of mutant KRAS.
The extension of tag-based strategies for control of target proteins in mouse models has been limited to studies using Shield-1-mediated stabilization of targets fused to a destabilizing FKBP12 domain 48 and degradation of HaloTag-HRAS G12V to reduce tumor burden in mice 8 . To our knowledge, other degron strategies, such as HaloPROTACs, SMASh, or AID have not been implemented in mouse studies. We employed a disseminated model of leukemia to non-invasively validate the use of the dTAG system for targeteddegradation studies in mice. The absolute selectivity, defined mechanism of action, and potent and rapid performance of dTAG-13 supports the broad utility of the dTAG system for biological research in mice.
In addition to our studies described herein, we recently employed the dTAG system to evaluate the consequences of acute degradation of ENL, a transcriptional regulator and core component of the super elongation complex, and MELK, a kinase previously implicated in promoting proliferation of breast cancer cells. We demonstrated that targeted degradation of ENL leads to genome-wide transcriptional defects, providing mechanistic insight into the role of ENL in leukemia pathogenesis 49 . By contrast, we established that targeted degradation of MELK is not required for the proliferation of basal-like breast cancer cells, arguing against further optimization of MELK inhibitors or degraders 50 . Our studies establish the extensibility of a chemical biology system for studying protein targets that we envision will broadly enable biological exploration and target validation in cells and in mice, notably in advance of direct-acting inhibitor or degrader drug molecules.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41589-018-0021-8.
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Methods
Molecule synthesis. Synthetic procedures and characterization of dFKBP-1, dTAG-7, dTAG-13, dTAG-48, dTAG-51, bio-SLF, and bio-Thal are detailed in the Supplementary Note.
Protein expression and purification. A construct containing residues 1-108 of FKBP12
WT or FKBP12 F36V in a gateway compatible pGEX-6P-1 vector (Amersham) was overexpressed in E. coli BL21 (DE3) in LB medium in the presence of 50 mg/ ml of carbenicillin. Cells were grown at 37 °C to an OD of 0.6, induced with 100 µ M isopropyl-1-thio-d-galactopyranoside (IPTG), incubated for 4 h at 37 °C, collected by centrifugation, and stored at − 80 °C. Cell pellets were resuspended in buffer A (50 mM HEPES pH 8.0, 250 mM NaCl, 0.1% Triton X-100, 1 mM TCEP), lysozyme was added to a concentration of 0.1 mg/mL, and the pellet was incubated at 4 °C for 15 min and subsequently sonicated. The resulting lysate was centrifuged at 15,000 × g for 20 min at 4 °C. Supernatant was added to equilibrated Glutathione Sepharose 4B beads (GE Healthcare), incubated overnight at 4 °C, and purified in batch mode with buffer A + 16 mM glutathione. Proteins were further purified on a HiLoad 16/600 Superdex 200 (GE Healthcare). Clean fractions were pooled and then frozen and stored at − 80 °C at a concentration of 0.44 mg/ml.
FKBP12
WT and FKBP12 F36V ligand-displacement AlphaScreen assay. In 384-well AlphaPlates (PerkinElmer), 90 nM GST-FKBP12 (WT or F36V) and 62.5 nM bio-SLF were diluted in 20 µ L assay buffer (PBS containing 0.1% BSA and 0.01%Triton X-100) containing competitor compound or DMSO. Following a 30-min incubation, 20 µ L detection solution containing Streptavidin Donor Beads and Glutathione Acceptor Beads diluted to 20 ng/µ L in assay buffer was added to each well. After a 1 h incubation at room temperature (20-25°C), luminescence was measured on an Envision 2104 plate reader (PerkinElmer). Percent activity values were calculated by setting the average background (no protein wells) to 0% and the average DMSO wells to 100% activity. Data were analyzed and plotted using GraphPad PRISM v6, and IC 50 values were determined using the 'log(inhibitor) vs. responseVariable slope (four parameters)' analysis module. Percent activity values were calculated by setting the average background (no protein wells) to 0% and the average DMSO wells to 100% activity. Data were analyzed and plotted using GraphPad PRISM v6, and IC 50 values were determined using the 'log(inhibitor) vs. response-Variable slope (four parameters)' analysis module.
CRBN-DDB1 ligand-displacement
CRBN-DDB1/FKBP12
F36V dimerization assay. Detection of chemical-induced dimerization was measured as previously described 1 . GST-FKBP12 F36V and CRBN-DDB1 (6× HIS-tagged) were diluted to 125 nM and 250 nM, respectively, in assay buffer (50 mM HEPES pH 7.4, 200 mM NaCl, 1 mM TCEP, and 0.1% BSA), and 20 µ L of protein mixture was added to each well of a 384-well AlphaPlate (PerkinElmer). Compounds were then added at 100 nL per well from DMSO stock plates using a Janus Workstation (PerkinElmer). Following a 1 h incubation at room temperature, 20 µ L Nickel Chelate AlphaLISA Acceptor and Glutathione AlphaLISA Donor beads (PerkinElmer) diluted to 20 ng/µ l in assay buffer was added to each well. After a 1-h incubation at room temperature, luminescence was measured on the Envision 2104 plate reader (PerkinElmer). Data were analyzed and plotted using GraphPad PRISM v6 and dimerization amplitude, mean, and s.d. values were determined using the 'Gaussian' analysis module.
Cell lines. MV4;11 (ATCC, RPMI1640 supplemented with 10% FBS, 100 U/mL penicillin, 100 μ g/mL streptomycin, and 2 mM glutamine), NIH/3T3 (ATCC, DMEM supplemented with 10% bovine serum, 100 U/mL penicillin, 100 μ g/mL streptomycin), 293FT and 293T (Thermo Fisher Scientific, DMEM supplemented with supplemented with 10% FBS, 100 U/mL penicillin, 100 μ g/mL streptomycin, and 2 mM glutamine) cells were cultured at 37 °C and 5% CO 2 . Cells matched their expected cell type morphology and were not independently verified. Cells routinely tested negative for mycoplasma using the MycoAlert kit (Lonza). None of the cell lines used are among those that are commonly misidentified as listed by ICLAC.
Lentivirus production and transduction. Lentiviral production was performed using 293FT cells, which were co-transfected with pMD2.G (Addgene, #12259), psPAX2 (Addgene, #12260), and dTAG lentiviral plasmids using Lipofectamine 2000 (Thermo Fisher Scientific), according to the manufacturer's instructions. Viral particles were collected 48 and 72 h after transfection, filtered through a 0.45 µ M membrane, and concentrated using 1:3 Lenti-X Concentrator (Clontech), according to the manufacturer's instructions. Concentrated viral supernatants were applied to NIH/3T3 and 293FT cells in the presence of 4 µ g/mL polybrene, and transduced cells were selected with 2 µ g/mL puromycin. MV4;11 cells were transduced by spinoculation with concentrated virus for 1 h at room temperature in the presence of 8 µ g/mL polybrene, and transduced cells were selected with 2 µ g/mL puromycin.
FKBP12
WT and FKBP12 F36V dual luciferase assay. 293FT cells were transduced with a lentiviral construct containing FKBP12
WT or FKBP12 F36V fused to nanoluciferase (Nluc). Nluc/Fluc plasmids were a kind gift from W. Kaelin (Dana-Farber Cancer Institute). Cells were plated at 2,000 cells per well in 40 µ L of appropriate media in 384-well white culture plates (Thermo Fisher Scientific). Cells were allowed to adhere overnight before addition of 100 nL of compound in DMSO from compound stock plates using a Janus Workstation pin tool (PerkinElmer). After addition of compound, plates were incubated for 24 h at 37 °C, before luminescence assessment. Plates were brought to room temperature before reagent addition. 20 µ L Fluc buffer (200 mM Tris, 15 mM MgSO 4 , 100 µ M EDTA, 1 mM DTT, 1 mM ATP, 200 µ M Coenzyme A, 400 µ M D-Luciferin, 0.1% Triton X-100) was added to each well for 15 min at room temperature, and luminescence was measured on the Envision 2104 plate reader (PerkinElmer). Subsequently, 20 µ L of Nluc buffer (25 mM Na4PPi, 10 mM NaOAc, 15 mM EDTA, 500 mM NaSO 4 , 500 mM NaCl, 24 µ M coelenterazine, 50 µ M 4-(6-methyl-1,3-benzothiazol-2-yl)aniline) was added to each well for 15 min at room temperature, and luminescence was measured on the Envision 2104 plate reader (PerkinElmer). Nluc values were normalized by dividing by control Fluc values. Nluc/Fluc ratios were then normalized by setting DMSO only wells to 100%. Data were analyzed and plotted using GraphPad PRISM v6 and IC 50 values were determined using the 'log(inhibitor) vs. response-Variable slope (four parameters)' analysis module.
IKZF1 dual luciferase assay.
A clonal 293T line stably transfected with pCMV-IRES-RenillaLUC-IRES-IKZF1-FireflyLUC reporter plasmid 18 (a kind gift from W. Kaelin, Dana-Farber Cancer Institute) was used to evaluate compound activity on IKZF1-Fluc fusion protein levels. Cells were plated at 2,000 cells per well in 50 µ L of appropriate media in 384-well white culture plates (Thermo Fisher Scientific). Cells were allowed to adhere overnight before addition of 100 nL of compound in DMSO from compound stock plates using a Janus Workstation pin tool (PerkinElmer). After addition of compound, plates were incubated for 24 h at 37 °C before luminescence assessment. Fluc and Rluc detection was performed as described above for the FKBP12 WT and FKBP12 F36V dual luciferase assay (with Rluc activity being measured using Nluc buffer). Fluc values were normalized by dividing by control Rluc values. Fluc/Rluc ratios were then normalized by setting DMSO-only wells to 100%. Data were analyzed and plotted using GraphPad PRISM v6, and IC 50 values were determined using the 'log(inhibitor) vs. responseVariable slope (four parameters)' analysis module.
FKBP12
F36V luciferase assay. MV4;11 cells expressing luciferase-FKBP12
F36V
were plated at 2,000 cells per well in 50 µ L of appropriate media in 384-well white culture plates (Thermo Fisher Scientific). 100 nL of compound in DMSO from compound stock plates was added to each well using a Janus Workstation pin tool (PerkinElmer). After addition of compound, plates were incubated for 16 h at 37 °C before luminescence assessment. Plates were brought to room temperature before addition of reagent. 25 µ L Fluc buffer (as described above for the FKBP12 WT and FKBP12 F36V dual luciferase assay) was added to each well for 10 min at room temperature, and luminescence was measured on the Envision 2104 plate reader (PerkinElmer). Luminescence values were then normalized by setting DMSO-only wells to 100%. Data were analyzed and plotted using GraphPad PRISM v6 using the 'log(inhibitor) vs. response-Variable slope (four parameters)' analysis module.
Immunoblotting. MV4;11 and 293T cells were lysed with RIPA buffer supplemented with halt protease inhibitor cocktail (Thermo Fisher Scientific) and 0.1% benzonase (Novagen) on ice for 60 min. Lysates were clarified by centrifugation at 20,000 × g for 10 min at 4 °C. NIH/3T3 and 293FT cells were lysed with RIPA buffer supplemented with cOmplete protease inhibitors (Roche) and PhosSTOP phosphatase inhibitors (Roche) on ice for 60 min. Lysates were clarified by centrifugation at 20,000 × g for 10 min at 4 °C. Protein concentration was determined by a BCA assay (Pierce), and all samples were run with equal total protein content. The following antibodies were used in this study: HA (Cell Signaling, #3724 and #2367), BRD4 long isoform (Bethyl labs, #A301-985A), BRD4 short isoform (Abcam, #ab128874), BRD3 (Abcam, #ab56342), BRD2 (Bethyl labs, #A302-582A), FKBP12 (Abcam, #ab24373), vinculin (Santa Cruz, #Sc-25336), GAPDH (Millipore, #MAB374), phospho-AKT S473 (Cell Signaling, #4060), AKT (Cell Signaling, #2920), phospho-MEK1/2 S221 (Cell Signaling, #2338), MEK1/2 (Cell Signaling, #4694), phospho-ERK1/2 T202/Y204 (Cell Signaling, #4370), ERK1/2 (Cell Signaling, #4696), phospho-Pol II S2 (Millipore, #04-1571-1), and Pol II (Santa Cruz, #Sc-899). GAPDH, vinculin, ERK1/2, MEK1/2, AKT, and Pol II were used as loading controls. Uncropped immunoblots are displayed in Supplementary  Figs. 11-15 . Imaging was performed by detection of fluorescently labeled infrared secondary antibodies (IRDye) on the Odyssey CLx Imager (LI-COR).
Lentiviral plasmid construction.
We deposited a set of plasmids, maps, and sequences for the lentiviral dTAG system to Addgene. To develop pLEX_305-NdTAG (Addgene, #91797) and pLEX_305-C-dTAG (Addgene, #91798) empty Articles NATURE ChEMICAl BIoloGy vectors, the pLEX_305 (Addgene, #41390) vector was modified. FKBP-2xHA cassettes were designed to include NheI and ClaI (N-dTAG) or AgeI and MluI (C-dTAG) restriction sites. Cassettes were synthesized by GeneScript and cloned into the pLEX_305 vector using the appropriate restriction sites.
Gateway recombination cloning technology (Invitrogen) was used to clone targets and controls of interest into pLEX_305-N-dTAG and pLEX_305-C-dTAG. pDONR plasmids for HDAC1, MYC, EZH2, PLK1, and BRD4 (short) were obtained from the Harvard PlasmID Repository, and KRAS G12V was obtained from Addgene (#31200) 51 . Luciferase was cloned into a Gateway compatible donor vector (pDONR223) using BP clonase after PCR with primers containing BP o ve rh angs G GG GA CA AG TT TG TA CA AA AA AG CA GG CT TA AC CA TG GA AG-ATGCCAAAAACATTAAGAAGGG (forward) and G GGGACCACTTTGTACA AGAAAGCTGGGTTCACGGCGATCTTGCCGCCCTT (reverse) from the dual luciferase vector described above. In brief, 150 ng pDONR vectors containing genes of interest were mixed with 150 ng of destination vector in 10 µ l. 2 µ l of LR clonase II enzyme mix (Life Technologies) was added to the plasmid mix and incubated for 1 h at room temperature. To terminate the reaction, 1 µ l of Proteinase K was added to each sample and incubated at 37 °C for 10 min. Samples were transformed using Stbl3-competent cells, plated on Ampicillin selective media, and grown at 30 °C. Colonies were picked and grown up in 50 mL LB medium overnight at 30 °C. Plasmid DNA was purified using midi-preps (Qiagen), and insertions were confirmed by BsrGI-HF digestion (NEB) and gel electrophoresis. Plasmids were sequenced using the primers listed in Supplementary Table 5 . Note that when designing plasmids for Gateway recombination cloning into the N-dTAG vector, a stop codon must be included at the end of the gene to prevent read-through into the recombination sequences. Supplementary Table 6 lists plasmids associated with the dTAG system. dTAG knock-in vector construction. We deposited a set of plasmids, maps, sequences, and protocols for the knock-in dTAG system to Addgene. To develop the pCRIS-PITChv2-BSD R -dTAG (BRD4) (Addgene, #91792) vector, the pCRISPITChv2-FBL (Addgene, #63672) 29 pX330A-nBRD4/PITCh (Addgene, #91794) was cloned as previously described 29, 52 . Briefly, N-terminal targeting guides for BRD4 were designed using http://crispr.mit.edu/. Oligonucleotides from IDT were annealed and inserted into the pX330A-1× 2 (Addgene, #58766) plasmid after BbsI (NEB) digestion to generate pX330A-1× 2-nBRD4. The PITCh sgRNA sequence from pX330S-2-PITCh (Addgene #63670) was inserted into pX330A-1× 2-nBRD4 using Golden Gate assembly (NEB). The resulting plasmid pX330A-nBRD4/PITCh contained the PITCh sgRNA, BRD4-specific sgRNA, and Cas9. Supplementary Table 6 lists plasmids associated with the dTAG system. BRD4 knock-in cell line development. 293T cells were plated in 10-cm plates and co-transfected with 1 µ g of pCRIS-PITChv2-BSD R -dTAG (BRD4) and 2 µ g of pX330A-nBRD4/PITCh using Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer's instructions. After 6 h of transfection, appropriate growth media was added to the cells for 48 h. Subsequently, cells were selected with 10 µ g/mL blasticidin, and single cell clones were isolated in 96-well format. To isolate genomic DNA, cells were washed twice with cold PBS, mixed with 60 μ L of directPCR (tail) (Viagen Biotech) and 0.4 mg/mL proteinase K (Life Technologies), transferred to a v-bottom PCR plate (VWR), and incubated overnight at 55 °C. To inactivate proteinase K, cells were incubated at 85 °C for 1.5 h. Cell debris was spun down at 500 × g for 5 min. To genotype the cells and confirm knock-in, PCR reactions were performed using 1 μ l of genomic DNA, 2× Q5 hot start master mix (NEB), and the following primers: TCCCTCTGGCCAACTTGGCTA (forward) and TGGTCTGCCTCTTGGGCTTGTTA (reverse). Amplified DNA was purified by gel extraction (Qiagen) and sequenced using the PCR primers. The same protocol was used for the C-terminal targeting plasmids pCRIS-PITChv2-dTAG-BSD R (BRD4) and pX330A-cBRD4/PITCh using the following primers: TACGGGGCTGACTGCTGGTA (forward) and AATCCTCAGCTGCCCGTCA (reverse). Although we did not successfully isolate C-terminal targeted clones with homozygous knock-in at the BRD4 locus, the pCRIS-PITChv2-dTAG-BSD R (BRD4) vector can be modified for C-terminal targeting of any gene of interest ( Supplementary Fig. 4 displays genotyping and validation of select clones). pX330A-cBRD4/PITCh was not deposited to Addgene as sgRNA cloning can be performed as described above.
Analysis of cell viability by ATPLite. 293T and NIH/3T3 cells were plated at 1,000 cells per well in 50 µ L of appropriate media in 384-well white culture plates (Thermo Fisher Scientific). Cells were allowed to adhere overnight before addition of 100 nL of compound in DMSO from compound stock plates using a Janus Workstation pin tool (PerkinElmer). After addition of compound, plates were incubated for 72 h at 37 °C, and ATPlite 1 Step Luminescence Assay System (PerkinElmer) was used to determine ATP-dependent luminescence as an approximation of cellular viability. Plates were brought to room temperature before reagent addition. Lyophilized powder was resuspended in lysis buffer and diluted 1:3 with deionized water. 20 µ L of this solution was added to each well, plates were incubated for 15 min at room temperature, and luminescence was measured on an Envision 2104 plate reader (PerkinElmer). Cell viability values were calculated by normalizing to DMSO-treated wells for each cell line. Data were analyzed and plotted using GraphPad PRISM v6 and the 'log(inhibitor) vs. response-Variable slope (four parameters)' analysis module.
Cell cycle analysis. 75,000 NIH/3T3 cells were plated in 6-well plates and allowed to adhere overnight. Cells were incubated with DMSO or 1 µ M dTAG-13 for 48 h, trypsinized, washed with PBS, and fixed in 70% ethanol at 4 °C overnight. Fixed cells were washed with PBS, resuspended in PBS with 100 µ g/mL RNase A (Thermo Fisher Scientific) and 50 µ g/mL propidium iodide (Sigma), and incubated at room temperature in the dark for 10 min. Guava EasyCyte flow HT (Millipore) was used to detect stained cells, and data was analyzed using FlowJo software (version 10.0.8r1, TreeStar).
Quantitative proteomics and phosphoproteomics. Sample preparation for mass spectrometry. Samples for peptide analysis were prepared as previously described 1 . Samples for phosphopeptide analysis were prepared as previously described 37 with the following modifications. Following tandem mass tag (TMT) labeling (1:4; peptide:TMT label, Pierce), phosphotyrosine (pY) peptides were enriched from the total phosphopeptide pool using pY-specific antibodies as described by the manufacturer (Cell Signaling, P-Tyr-100). The pY enriched peptide data was collected as a single 3 h run on the mass spectrometer. The flow through from the pY-enrichment was used to collect the phosphoserine/threonine data as previously described 37 .
Liquid chromatography-MS3 spectrometry (LC-MS3
). An Orbitrap Fusion mass spectrometer (Thermo Fisher Scientific) equipped with a Proxeon Easy nLC 1000 was used to analyze peptide fractions with an LC-MS3 data collection strategy, as previously described , maximum injection time 100 ms, dynamic exclusion of 60 s). For MS2 analysis, the top 10 precursors ('Top N') were selected, which consisted of CID ion trap analysis (AGC 1.5 × 10 4 , NCE 35, maximum injection time 150 ms), and quadrapole isolation of 0.5 Da for the MS1 scan. For MS3 analysis, the top ten fragment ion precursors from each MS2 scan were selected (synchronous precursor selection), in which precursors were fragmented by HCD before Orbitrap analysis (NCE 55, max AGC 1.5 × 10 5 , maximum injection time 150 ms; MS2 quadrapole isolation was set to 2.5 Da, resolution 50,000).
The scan sequence for the 12 phosphoserine/threonine fractions for the Fusion Orbitrap began with an MS1 spectrum (Orbitrap analysis, resolution 120,000, 400− 1,400 m/z scan range with quadrapole isolation, AGC target 2 × 10 5 , maximum injection time 100 ms, dynamic exclusion of 75 s). For MS2 analysis, the top 10 precursors ('Top N') were selected, which consisted of CID ion trap analysis (AGC 8 × 10 3 , NCE 35, maximum injection time 150 ms) and quadrapole isolation of 0.5 Da for the MS1 scan. For MS3 analysis, the top three fragment ion precursors from each MS2 scan were selected (synchronous precursor selection), in which precursors were fragmented by HCD before Orbitrap analysis (NCE 55, max AGC 1 × 10
5
, maximum injection time 250 ms; MS2 quadrapole isolation was set to 2.5 Da, resolution 60,000).
The scan sequence for the single pY sample for the Lumos Orbitrap began with an MS1 spectrum (Orbitrap analysis, resolution 120,000, 400− 1,350 m/z scan range with quadrapole isolation, AGC target 1 × 10 6 , maximum injection time 100 ms, dynamic exclusion of 60 s). For MS2 analysis, the top 10 precursors ('Top N') were selected, which consisted of CID ion trap analysis (AGC 2.5 × 10 4 , NCE 35, maximum injection time 150 ms), and quadrapole isolation of 0.5 Da for the MS1 scan. For MS3 analysis, the top ten fragment ion precursors from each MS2 scan were selected (synchronous precursor selection), in which precursors were fragmented by HCD before Orbitrap analysis (NCE 55, max AGC 2.2 × 10 5 , maximum injection time 150 ms; MS2 quadrapole isolation was set to 1.2 when z = 2 or 1 when z = 3 or 0.8 when z = 4-6, resolution 60,000).
LC-MS3 data analysis.
In-house software tools were used to process the data as previously described 1 with the following modification. Database search criteria also included variable phosphorylation of serine, threonine, and tyrosine (79.96633 Da) for pST or pY searches.
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RNA-sequencing with ERCC RNA spike-in normalization. 350,000 NIH/3T3 cells were plated in 6-well plates and allowed to adhere overnight. NIH/3T3 cells were treated as indicated, lysed, homogenized using Qiashredder columns (Qiagen), and RNA was extracted using the RNeasy Plus Mini Kit (Qiagen), according to the manufacturer's instructions. Cell-count-normalized RNA samples were mixed with the ERCC RNA Spike-In Mix #1 (Life Technologies) before library preparation. Libraries for Illumina sequencing were prepared using TruSeq Stranded mRNA Library Prep Kit (Illumina), and equimolar multiplexed libraries were sequenced on an Illumina NextSeq 500 (single end 75 bp reads) by the Molecular Biology Core Facility at the Dana-Farber Cancer Institute. Fastq files were aligned to mouse genome build mm9 using HiSat with default parameters. Transcripts were assembled, and FPKM values were generated using cuffquant and cuffnorm from the cufflinks pipeline 53 . FPKM values were then normalized to synthetic ERCC spike-in RNAs as described previously 54 . A transcript was considered expressed in each data set if in one experimental condition the average FPKM > 2.0 and in one experimental condition 2 out of 3 replicates had an FPKM > 2.0. snoRNAs, miRNAs, histone genes, ribosomal genes, and ERCC spikein transcripts were removed from the analyses. Gene Set Enrichment Analysis (GSEA) 55 was performed using curated gene sets (C2) between experimental conditions. Significantly differentially expressed genes between experimental conditions were uploaded to the Ingenuity Pathway Analysis tool for functional and pathway enrichment analysis as previously described 43 .
Animal studies. /SzJ, NSG; Jackson Laboratory #005557) by tail-vein injection. Prior to transplantation, cells were tested at Charles River Laboratories to ensure lack of contaminating mycoplasma and rodent-infectious agents (Mouse Comprehensive Panel). Bioluminescence was used to monitor engraftment for two weeks, at which point mice were assigned to vehicle (n = 6 biologically independent mice) or dTAG-13 (25 mg/kg, n = 5 biologically independent mice) cohorts such that cohorts had similar variability in bioluminescent signal. Mice with no engraftment were excluded from the study. For treatments, dTAG-13 was formulated in a 20% solutol (Sigma), 5% DMSO solution in 0.9% sterile saline (Moltox) and intraperitoneal injections were performed. Each cohort was dosed, and bioluminescence was monitored at the time points indicated in Supplementary  Fig. 10a . This animal experiment (protocol #13-053) was approved by the DanaFarber Cancer Institute Animal Care and Use Committee (IACUC) and all experiments were adherent to institutional standards.
Pharmacokinetic assessment was performed at Shanghai ChemPartners Co., LTD. In brief, 1 mg/kg dTAG-13 and two other dTAG compounds (3 in 1 cassette dose) were administered via intraperitoneal injection to CD1 male mice (Shanghai SLAC Laboratory Animal Co. LTD, Certificate No.: SCXK (SH), 2012-0002 2015000512058, n = 3 biologically independent mice). Approximately 25 µ L of blood from the facial vein of a mouse was collected into a K2EDTA tube at the following time-points: pre-dose, 0, 0.083, 0.25, 0.5, 1, 2, 4, 8 and 24 h. 20 µ L of blood was diluted with 60 µ L sterile water, put on dry ice immediately after collection, and stored at approximately − 70 °C until analysis. 30 µ L of diluted blood sample was added to 150 µ L acetonitrile containing 100 ng/mL internal standard (Diclofenac). The mixture was vortexed for 10 min and centrifuged at 5,228 × g for 10 min, and 5 µ L of the supernatant was used for LC-MS/MS analysis. MS analysis was performed using an AB SCIEX API4000 triple-quadrupole instrument with an electrospray ionization interface. The data acquisition and control system were created by using Analyst 1.5.2 software from AB SCIEX. The lower limit of quantification was 2.00 ng/mL in mouse blood samples. This animal experiment (protocol #A998HL0002) was approved by the Shanghai ChemPartners Co., LTD IACUC and all experiments were adherent to institutional standards.
Statistical analyses.
Statistical tests are identified in the corresponding figure legends. Center values, error bars, P value cutoffs, number of replicates or samples, and number of independent experiments are detailed in the corresponding figure legends. Error bars are shown for all data points with replicates as a measure of variation within each data group. Data met the assumptions for all tests used and sample sizes were not predetermined using any statistical analyses. The experiments were not randomized, and the investigators were not blinded to allocation during experiments and outcome assessment.
Life Sciences Reporting Summary. Further information on experimental design is available in the Life Sciences Reporting Summary.
Data availability. RNA-sequencing data reported in this paper has been deposited to the NCBI GEO and are available under the accession number GSE92775. Normalized and scaled quantitative mass spectrometry-based proteomics and phosphoproteomics (phosphoserine/threonine and phosphotyrosine) data are provided in Supplementary Datasets 1 
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